Illumina, Inc. (ETR:ILU)

Market Cap	18.62B -11.3%
Revenue (ttm)	3.67B -2.3%
Net Income	601.21M
EPS	3.81
Shares Out	n/a
PE Ratio	30.98
Forward PE	28.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	382
Average Volume	314
Open	120.36
Previous Close	122.62
Day's Range	118.68 - 121.40
52-Week Range	62.00 - 132.16
Beta	1.13
RSI	50.94
Earnings Date	Feb 5, 2026

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 9,030
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ILU

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD